CD38 and plasma cell myeloma: Interestingly, a very recent study by Verkleij et al. [98] showed that a long duration treatment with anti-mousePD-1 mAb markedly improved anti-mouse CD38 ADCC in vivo in murine CD38+ myeloma model J558 and other CD38+ tumors.